38,39 For that reason, since 2017, for TB/HIV patients meeting the criteria of severe disease – i.e., CD4 cell count < 100 cells/μL, disseminated TB, other concomitant opportunistic infection, and hospitalized patients –, the recommended ART regimen was to include raltegravir; and efavirenz-based treatment was recommended for TB/HIV without severe disease. The gene discussed is CD4; the disease is Opportunistic infection.